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Available online at www.sciencedirect.comThe most widely used anticancer drugs are platinum-based.
Their efficacy might be improved by carriers which can
transport large numbers of Pt centres, shield the drug from
premature activation, and/or deliver Pt specifically to cancer
cells using vectors which recognise specific targets. We
describe recent progress using functionalized carbon
nanotubes (CNTs) and nanorods, hollow Prussian blue (HPB),
magnetic iron oxide and gold nanoparticles, liposomes,
nanogels and polymers, as well as active targeting by
conjugation to biodegradable proteins and peptides (e.g. EGF,
heparin, herceptin, somatostatin and TAT). Spatially targeted
activation of PtIV prodrugs using light is also a promising
approach. Interestingly, use of these new delivery and targeting
systems for platinum drugs can lead to species with unusual
reactivity which can kill cancer cells by new mechanisms.
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Introduction
Cisplatin, cis-[PtCl2(NH3)2] (CDDP), is well known for
both its anticancer activity and systematic toxicity.
Hydrolysis of cisplatin generates active PtII aqua species
which induce apoptosis in cancer cells due to the formation
of 1,2-d(GpG) intrastrand DNA cross-links [1]. Side-
effects and deactivation may arise from the reactions of
active PtII aqua species with proteins. The later generation
complexes carboplatin and oxaliplatin on the one hand can
exhibit less side-effects, and on the other hand, can exhibit
activity against cisplatin-resistant cancers [2]. However,
targeted delivery of platinum drugs specifically to tumour
cells of patients remains to be addressed. The major
limitations of chemotherapeutic agents are often difficul-
ties with solubility, formulation, biodistribution and ability
to cross cell membranes. These problems have prompted
the exploration of various scaffolds to act as vectors for
targeted delivery of platinum-based anticancer complexes.
Targeted delivery is a well-known field in which the drug
Open access under CC BY license.www.sciencedirect.com carriers target tumour cells via two different processes;
passive or active drug delivery. The former exploits the
tumour vascular system through the enhanced per-
meability and retention (EPR) effect (the tendency for
macromolecules and nanoparticles to accumulate more in
tumour than in normal tissues), whereas, active drug deliv-
ery utilizes receptor-type conjugates which drive the drug
towards the tumour cells. Wang et al. have discussed these
processes in detail [3]. Here we summarise recent
advances in both passive and active delivery of
platinum-based anticancer complexes.
Untargeted passive drug delivery
Utilizing nanotechnology to improve drug delivery is a
well-known concept, however innovative designs of
nano-vectors to achieve efficient drug delivery and their
complexity are emerging [4]. Carbon nanotubes (CNTs)
are the most studied. Pristine CNTs are insoluble in most
solvents and bear structural resemblance to carcinogenic
asbestos fibres. However, coating CNTs with linear and/
or branched poly(ethylene glycol) (PEG) units (1 and 2,
Figure 1a) renders them more hydrophilic and more
suitable for biomedical applications [5]. The toxic nature
of pristine (non-functionalised) multi-walled and single-
walled CNTs and ability to induce mesothelioma have
been demonstrated. Bianco et al. have shown that mono-
functionalisation, bi-functionalisation, and tri-functiona-
lisation of CNTs (3–5, Figure 1b) give enhanced bio-
compatibility and can be translocated directly into the
cytoplasm of cells. Non-biodegradable CNTs have the
potential to accumulate in various tissues and organs [6],
however the oxidative enzyme horseradish peroxidase
(HRP) can catalytically degrade f-CNTs [7].
Tripisciano et al. have encapsulated CDDP into functio-
nalised single-walled carbon nanotubes (SWCNTs).
CDDP-SWCNTs are more cytotoxic than free CDDP
towards PC3 cancer cells, but less potent than CDDP
towards DU145 cells [8]. Recently, Li et al. capped
multi-walled carbon nanotubes (MWCNTs) with
functionalized 1-octadecanethiol (ODT) gold nanoparti-
cles ( f-GNPs) to facilitate the effective delivery of CDDP
(6). The presence of the f-GNP at the tip of the MWCNTs
hinders the encapsulated CDDP from leaving the narrow
passage of the MWCNTs. The in vivo activity of CDDP in
capped CDDP-MWCNTs towards MCF-7 breast cancer
cells was enhanced (IC50 7.7 mM), compared to uncapped
CDDP-MWCNTs (IC50 11.7 mM). These results suggest
that f-GNP MWCNTs may be effective drug depots [9].
Reducing the size of the CNTs renders them more likely
to pass into the cell, as seen for SWCNTs of 1–2 nmCurrent Opinion in Chemical Biology 2013, 17:175–188
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Targeted delivery of platinum-based anticancer complexes Butler and Sadler 177diameter. Guven et al. have synthesised ultra-short carbon
nanotubes (USCNTs) of ca. 1.4 nm diameter in which
CDDP was encapsulated (7) and then wrapped with a
surfactant. The CDDP-USCNTs were more potent than
free CDDP in two breast cancer cell lines (MCF7 and
MDA-MB-231) after 24 hours. Wrapping of USCNTs
with a surfactant retards release of CDDP resulting in
its higher cytotoxicity. For in vivo use, the surfactant
molecules could be replaced with a cancer-specific
protein [10].
Li et al. have entrapped a hydrophobic PtIV complex (8)
within the inner cavity of MWCNTs. Chemical reduction
converted the PtIV prodrug to its hydrophilic and cyto-
toxic PtII form triggering its release from the MWCNTs.
Incubation of 8-MWCNTs in the presence of deoxygua-
nosine monophosphate (dGMP) did not produce any PtII-
DNA adducts in the absence of the bio-reductant ascorbic
acid. These results indicated that chemical reduction was
required for the formation of the PtII species which bind
to DNA. In vitro studies showed that 8-MWCNTs were
efficiently delivered into A2780 human ovarian carcinoma
cancer cells in comparison to the free PtIV prodrug which
was readily dissipated into the ambient environment [11].
Ajima et al. have incorporated cisplatin into single-wall
carbon nanohorns (SWCNHox). SWCNHox offer various
advantages over conventional CNTs. The in vitro cyto-
toxicity of cisplatin in SWCNHox was ca. four to six fold
greater than free CDDP towards human lung cells, NCI-
H460 [12].
Dhar et al. have tethered a PtIV complex via amide linkages
to AuNPs functionalised with thiolated 28-mer oligonu-
cleotides (9). Pt-DNA-Au nanoparticles were most active
in A549 lung cancer cells, displaying cytotoxicity ca. 12-
fold higher than free CDDP [13]. Min et al. have con-
jugated a PtIV prodrug (10) to amine-functionalised PEGy-
lated gold nanorods (AuNRs); it is reduced to PtII by
cellular reductants. Nanorods possess longer circulation
times than nanoparticles rendering their accumulation
more efficient within tumour cells. The PtIV-PEG-AuNRs
were most active in the MCF-7 breast cancer cells, exhi-
biting an IC50 of 0.18 mM, significantly more potent than
free cisplatin IC50 of 11.8 mM [14].
In similar work, Brown et al. functionalised AuNPs with
thiolated PEG tethered to the active fragment of oxali-
platin, {Pt(R,R-dach)}2+ (11 and 12, Figure 1h). Similarly,
these Pt-AuNPs were almost 6x more active towards A549
lung cancer cells than free oxaliplatin but ca. 5x more(a) PEGylated carbon nanotubes, linear (1) and branched (2). (b) Mono-func
nanotubes. (c) Carbon nanobottle with encapsulated CDDP capped with f-Au
(7). (e) Hydrophobic PtIV complex (8). (f) Encapsulation of PtIV complex within
(10). (h) Active component of oxaliplatin tethered to AuNP functionalised with
nanoparticles impregnated with starch (13). (j) CDMP encapsulated within s
carboxymethylcellulose (14). (k) Poly(g,L-glutamic acid)–citric acid conjugate
www.sciencedirect.com active, or as active, as free oxaliplatin in various colon
cancer cell lines [15]. These results demonstrate
increased potency of platinum complexes conjugated to
gold nanoparticles/rods.
Use of inorganic nanoparticles to overcome multidrug
resistance is being explored [16]. Treatment of T24
bladder cancer cells with aqueous CDDP loaded into
hollow Prussian blue (HPB) nanoparticles results in
breakage of the cell membrane and changes in cell
morphology indicative of cell death. HPB nanoparticles
show potential as future vectors owing to their biocom-
patibility, although their size needs to be optimised to
allow a higher percentage of loaded cisplatin to be
released [17].
Likhitkar et al. have developed a novel method for the
synthesis of superparamagnetic (SPM) nanoparticles
impregnated with nano-sized iron oxide loaded with
aqueous cisplatin (13). Cisplatin was released in both
the absence and presence of a magnetic field through a
controlled diffusion pathway. However, the quantity of
cisplatin released was influenced by pH and temperature
of the medium in addition to the presence of an external
magnetic field [18].
Xing et al. have synthesized superparamagnetic magnetite
nanocrystal clusters modified with carboxymethylcellu-
lose (CMC) in which {PtCl(NH3)2}
+ was tethered through
carboxylate groups on the surface (14). The CMC-SPM
clusters were non-toxic towards both human cervical
(HeLa) and hepatocarcinoma (HepG2) cells. While,
CMDP–CMC–SPM clusters were more active (0.9 mM)
than CDDP (2.6 mM) towards HeLa cells, in HepG2 the
CMDP–CMC–SPM clusters were only 1.2-fold more
active than CDDP. Similar to other platinum delivery
systems, the release of the platinum pharamacophore
from the CMDP-CMC-SPMNC is facilitated by the
acidic environment of the tumour [19].
Superparamagnetic iron oxide nanoparticles (SPIONs)
are biocompatible, biogradable, have good aqueous solu-
bility and magnetic properties. Pectin is a suitable drug
carrier for colon-specific drug delivery owing to its resist-
ance to both protease and amylase. Dutta et al. have
encapsulated both SPIONs and oxaliplatin in situ into
pectin cross-linked with Ca2+ forming pectin nanocar-
riers. These magnetic nanocarriers exhibited cytotoxicity
10-fold higher than free oxaliplatin towards MIA-PaCa-2
pancreatic cancer cells [20].tionalised (3), bi-functionalised (4) and tri-functionalised (5) carbon
NPs (6). (d) Encapsulation of cisplatin by single-walled carbon nanotubes
 AuNP functionalised with oligonucleotides (9). (g) PtIV prodrug complex
 PEG linker (11, 12). (i) Monohydroxido cisplatin conjugated to iron oxide
uperparamagnetic iron oxide nanoparticles modified with sodium
d to cis-diammine PtII (15).
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Targeted delivery of platinum-based anticancer complexes Butler and Sadler 179The cisplatin nanoconjugate, g-PGA-CA-CDDP is a
hydro-soluble polymer of g-polyglutamic acid (g-PGA)
modified with citric acid (CA) conjugated with diaqua
cisplatin (15, Figure 1k). Sustained release of the nano-
conjugate indicated its improved selectivity and effi-
ciency. However, 15 was less potent than free CDDP
towards both BcaP-37 human breast and Bel-7402 liver
cancer cell lines [21].
Targeted active drug delivery through cancer-
cell specific vectors
While delivery of anticancer agents via nanocarriers is
efficient for reaching the tumour site through the EPR
effect, correct attachment of receptor-binding molecules
(particularly for receptors overexpressed in cancer
tissues) on the surface of NPs can enhance the uptake
of the nanocarrier into the tumour cell through receptor-
mediated internalisation. The most common receptors
targeted in nanotechnology include the folate (FR),
epidermal growth factor (EGF) and transferrin (TfR)
receptors.
Rout et al. have conjugated cis-diaquadiammine PtII, folic
acid (FA) and rhodamine B isothiocyanate onto magnetic
calcium phosphate nanoparticles for the targeted deliv-
ery of CDDP into HeLa human cervical cancer cells (16).
The cytotoxicity of 16 towards both HeLa (FR +ve) and
L929 (FR ve) human cervical cancer cells was ca.
fourfold and onefold, respectively, more active compared
to free CDDP, indicating that the nano-agent selectively
targeted the HeLa cells through receptor mediated
endocytosis [22]. Coencapsulation of AsIII-based and
cisplatin-based anticancer complexes in a folate-functio-
nalised liposome, referred as a ‘‘nanobin’’ (17), provided
efficient drug delivery and uptake in KB human naso-
pharyngeal cells (FR +ve), but not in MCF-7 breast
cancer cells (FR ve) [23].
Nanogels are swollen polymers containing ca. 95%
water suitable for trapping a range of chemical and
biological agents. Nukolova et al. have investigated
the antitumour activity of nanogels conjugated with
folic acid (18) and loaded with CDDP. Uptake into
A2780 human ovarian carcinoma cells (FR +ve)
depended on whether CDDP was loaded before or after
folate attachment. In contrast, for A549 lung cancer cells
(FR ve), the uptake was independent on the sequence
of loading. The FR-nanogel-CDDP  displayed superior
antitumour activity towards A2780 xenografts in con-
trast to free CDDP [24].(a) Conjugation of cisplatin, folic acid and rhodamine B isothiocyanate to am
Coencapsulation of arsenic and platinum into a folate-PEGylated functionalis
conjugated with cisplatin and epidermal growth factor (19). (e) Gelatin-Pt na
nanoparticles with encapsulated CDDP (21). (g) Dumbbell gold-iron oxide n
encapsulated within liposomes functionalised with Tf and DOPE (23). (i) CD
Platinum-TSPO-binding ligand conjugates with various X groups (26, 27). (l)
www.sciencedirect.com The intracellular delivery of carboplatin has been inves-
tigated by coupling i.p. administration with a folate-re-
ceptor-targeted liposomal system. The cytotoxicity is
enhanced (twofold) in comparison to carboplatin itself
towards human ovarian IGROV-I (FR +ve) cancer cells.
Mice bearing the i.p.-grown human IGROV-1 ovarian
tumour xenografts treated with FRT-carboplatin lipo-
somes had an 83% survival rate [25].
EGF is another potential targeting ligand due to the
overexpression of the EGF receptor in human tumours,
in particular NSCLC non-small cell lung cancer. Bhirde
et al. have attached cisplatin (dissolved in DMSO) and
EGF to oxidised SWCNTs to target squamous cancer. In
vivo studies revealed SWCNT–CDDP–EGF (19) were
selective towards HNSCC head and neck squamous cell
carcinoma. Tumour growth regression was significant in
mice treated with SWCNT–CDDP–EGF bearing
HNSCC xenografts in contrast to mice treated with
SWCNT–CDDP [26]. Biotinylated epidermal growth
factor (bEGF) conjugated to a {Pt(NH3)2}
2+-gelatin nano-
complex (GP-Pt-bEGF, 20) gives rise to a twofold higher
Pt concentration in A549 human adenocarcinoma (EGF
+ve) compared to HFL1 lung fibroblasts (EGF ve).
Immunodeficient mice injected with an A549 cell sus-
pension treated with GP-Pt-bEGF nanoparticles dis-
played a reduction in tumour volume compared to
mice treated with free CDDP which the tumour volume
grew rapidly [27].
The high molecular weight of full length EGFR mono-
clonal antibody if used as a targeting ligand may hinder its
penetration into tumour cells; furthermore interaction
with the Fc receptor on normal tissues may disturb its
specific targeting. Therefore, single-chain antibodies
against the EGFR (ScFvEGFR) lacking the Fc receptor
have been conjugated onto the surface of ScFvEGFR-
heparin-CDDP nanoparticles (with {Pt(NH3)2}
2+ bound
to carboxylates, 21). Nanoparticle conjugate 21 was most
potent towards H292 (EGF +ve) human lung cancer cells
with an IC50 of 1.1 mM. Kidneys from mice treated with 21
showed no change in either blood urea nitrogen (BUN) or
creatine (CRE) levels, in contrast to CDDP which gave
significant changes consistent with impaired renal func-
tion [28].
Xu et al. have coupled a {Pt(NH3)2}-herceptin (L2,
Figure 2g) dicarboxylato binding ligand onto dumbbell-
like Au-Fe3O4 nanoparticles (22) to act as nanocarriers to
deliver the platinum pharamacophore into SK-Br3 breastorphous calcium phosphate/CoFe2O4 nanoparticles (16). (b)
ed liposome (17). (c) Folate functionalised nanogel (18). (d) SWCNT bio-
noparticles with biotinylated EGF (20). (f) EGF-targeted heparin
anoparticles coupled with herceptin and CDDP (22). (h) Oxaliplatin
DP-F3-targeted nanoparticles (24). (j) PtIV-chlorotoxin conjugate (25). (k)
 PtII peptide conjugates (28, 29).
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Targeted delivery of platinum-based anticancer complexes Butler and Sadler 181cancer (HER2 +ve) cells. Without the targeting agent, the
platin-Au-Fe3O4-NPs were still active, but less than
CDDP. Thus, herceptin enhances Pt uptake in SK-Br3
cells giving greater cytotoxicity owing to the specific
targeting. The platin-Au-Fe3O4-herceptin NPs did not
display any improvement in cytotoxicity towards MCF-7
breast cancer (HER2 ve) cells [29].
Krieger et al. have synthesised both transferrin-targeted
and non-targeted PEGylated cisplatin-containing lipo-
somes. Free CDDP displayed strong differences in cyto-
toxicity towards A2780 and resistant A2780cis breast
cancer cells, whereas the liposomes all displayed com-
parable cytotoxicity in both cell lines. Thus, these lipo-
somes are potential carriers to treat cisplatin-resistant
tumours [30]. Liposomes encapsulating oxaliplatin and
with bound human transferrin (23) show potency in vitro
towards colon, pancreatic and neuroendocrine human
cancer cells [31].
Peptides
The F3 peptide is a 31-residue fragment of the high
mobility group protein (HMGN2) which has potential to
bind to the nucleolin protein expressed on both the
surface of endothelial and tumour cells. Winer et al. have
encapsulated CDDP in a polyacrylamide nanoparticle
functionalised with the F3 peptide. Complex 24 dis-
played significant cytotoxicity towards tumour
endothethial cells (TECs). Using a model of human
tumour vasculature, it was shown that the F3-Cis-NPs
bind to human tumour vessels [32]. These results suggest
the safety of F3-Cis-Nps and effectiveness for targeting
TECs.
Various peptide sequences can bind preferentially to
tumour cells and thus can act as cancer targeting ligands.
For example, chlorotoxin (CTX), a 36-amino acid peptide
which blocks small-conductance chloride channels, binds
to functional proteins such as matrix metalloproteinase-2
(MMP2) (overexpressed in glioma and related cancers)
and chloride ion channels overexpressed in different
types of cancers. CTX has been conjugated to a PtIV-
succinato complex (25) as a prodrug for delivery of
cisplatin. The cytotoxicity of 25 towards MCF-7 breast,
A549 lung and HeLa cervical cancer cells was less than
CDDP but greater than both the PtIV precursor and CTX
alone. The kinetic inertness of the PtIV complex probably
contributes to its reduced activity [33].
Translocator proteins (TSPOs) are peripheral benzo-
diazepine receptors (PBRs) overexpressed in both human(a) Platinum(IV)-succinato peptide conjugates (31–35). (b) Oxaliplatin-TAT m
functionalised with PLGA-PEG with CDDP encapsulated in the core (38). (d) M
functionalised with PSMA aptamer and PEG (40). (f) Example of cis (41) and
complexes (43–45). (h) ProLindacTM (46). (i) Platinum (47 and 48) and NO-p
conjugates (50–52). (j) Bi(PEG-PLGA)-platinum(IV) polymer prodrug conjuga
www.sciencedirect.com and rat glioma cells. Margiotta et al. have conjugated cis-
{PtII(NH3)(X)2} to TSPO-binding ligands (Figure 2k).
Such conjugates showed potency equivalent to that of
cisplatin through apoptosis. The iodido complex 26 was
slightly more potent than the chlorido derivative 27;
however, unlike CDDP, both complexes were equally
active towards sensitive A2780 and resistant A2780cis
breast cancer cells [34].
The targeting sequence NGR (Asn-Gly-Arg) can bind
specifically to murine breast cancer cells. Two peptide
conjugates of the type cyclic mPEG-CNGRC-Pt and
cyclic mPEG-CNGRC-Pten (Figure 2l, 28 and 29)
showed selective delivery and more effective destruction
of PC-3 prostate (CD13 +ve) cells than the untargeted
platinum complex, carboplatin [35].
The 13-amino acid peptide neurotensin (pNT) and NT1
and NT3 receptors are upregulated in colon, pancreatic
and prostate cancers. Somatostatin (growth-inhibiting
hormone) is a cyclic tetradecapeptide overexpressed in
a variety of neoplastic tumours, but has a short natural
lifetime. Analogues such as octreotate (tate) a cyclic
octapeptide, possess longer lifetimes owing to the pre-
sence of D-amino acids. Gaviglio et al. have prepared four
conjugates of a PtIV-succinato complex (10, as a CDDP
prodrug) with both pNT and tate peptides (Figure 3a). All
four conjugates (31-35) displayed similar IC50 values to
that of the precursor in the MCF-7 breast cancer cells.
Additionally, in the HepG2 human hepatocytes and
PT45 pancreatic cell lines, the presence of an extra tate
residue (35) did not enhance interaction with the SSTR2
receptor [36].
Cell penetrating peptides (CPPs) are another well-
known class of drug carriers due to their ability to pass
through cell membranes. The TAT peptide is a widely
studied CPP. Conjugates of the TAT peptide
(YGRKKRRQRRR) with a PtIV analogue of oxaliplatin
generated complexes (36 and 37, Figure 3b) were >4
more potent in ovarian, colon and lung cancer cells lines
than the free PtIV analogues of oxaliplatin. The diconju-
gate 37 displayed slightly lower cytotoxicity, indicating
that an extra TAT peptide does not enhance the cyto-
toxicity [37].
Integrins, heterodimeric cell-adhesion proteins associ-
ated with tumour angiogenesis and metastasis, are upre-
gulated in tumour cells compared to low levels in normal
endothelial cells. Polymer NPs with a PtIV cisplatin
prodrug (38, Figure 3c) encapsulated in the core andono-peptide (36) and di-peptide (37) conjugates. (c) Nanoparticles
itaplatin (39). (e) Platinum(IV) prodrug encapsulated within nanoparticles
 trans (42) steroidal platinum(II) complexes. (g) Vitamin B12-platinum(II)
rodrug (49) poly(acrylic acid) star conjugates. (k) Platinum(IV) polymer
te (53).
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182 Bioinorganic Chemistrytargeted to avb3 integrin-expressing cells using the cyclic
pentapeptide c(RGDfk) (38) showed a 6-fold enhance-
ment in the in vitro cytotoxicity towards MCF-7 breast
cancer cell lines compared to CDDP. In vivo studies
revealed equivalent tumour growth inhibition (ca. 60%)
by both 38 and cisplatin in mice bearing A2780 xenografts
[38].
The Warburg effect, the ability of cancer cells to produce
energy through a high rate of glycolysis, helps tumours cells
survive. The FDA-approved anticancer agent dichloroa-
cetate (DCA) can reverse the Warburg effect. The PtIV
prodrug Mitaplatin (39) contains two DCA units, and once
internalised is reduced to cisplatin which can attack nuclear
DNA, while the DCA can attack mitochondria selectively.
Mitaplatin alters the mitochondrial membrane potential of
cancer cells, promoting apoptosis by releasing cytochrome
c and translocating apoptosis-inducing factor from mito-
chondria to the nucleus. The cytotoxicity of 39 is equiv-
alent or exceeds most well-known PtIV complexes and is
comparable to CDDP [39].
Phase I, II and III trials of LipoplatinTM (composed of
8.9% cisplatin and 91.1% lipids, w/w, with an average
diameter of 110 nm) have reported no renal toxicity.
Stathopoulos et al. have investigated the use of lipoplatin
as both a mono-therapy and in combination with taxanes
in cancer patients with renal insufficiency. The lack of
increase in CRE levels suggest a potential future use for
lipoplatin in patients with renal insufficiency [40].
With the aim of targeting prostate cancer (PCa), a PtIV
prodrug (for CDDP) has been encapsulated into aptamer
(Apt)-targeted poly (D,L-lactic-co-glycolic acid)-b-poly(-
ethylene glycol) (PLGA-b-PEG) nanoparticles (NPs)
forming a Pt-PLGA-b-PEG-Apt-NP conjugate (40)
engineered to target the prostate-specific membrane anti-
gen (PSMA). These nanoparticles demonstrated
enhanced in vivo pharmacokinetics (PK), biodistribution,
tolerability and efficacy. The maximum tolerated dose
(MTD) for Pt-PLGA-b-PEG-NP was 40 mg/kg while that
of CDDP and the prodrug alone was 20 mg/kg. The Pt in
40 remained in systemic circulation one hour post-admin-
istration [41], longer than for cisplatin itself.
Since the androgen receptor (AR) is upregulated in breast,
ovarian and prostate tumour cells, Huxley et al. have
designed multiple androgenic steroidal ligands with various
nitrogen-containing heterocyclic rings conjugated to either
cis-platin or trans-platin (41 and 42, Figure 3d) as platinum
drug delivery vectors. These [PtII(NH3)2Cl(steroid)] con-
jugates were 2–12-fold more cytotoxic than the non-
steroidal complexes, but with a similar activity range as
CDDP. Interestingly, the cis-complex conjugates displayed
two to threefold higher activity than their trans analogues.
Conjugation to lipophilic testosterone appears to help the
cationic complexes through the cell membrane [42].Current Opinion in Chemical Biology 2013, 17:175–188 Many proliferating cells have a high demand for cobala-
min (Cbl, coenzyme vitamin B12) making it an attractive
carrier. Enzymatic reduction of complexes of the type
B12-CN-Pt
II (Figure 3g) releases PtII diammine com-
plexes. Complex 43 was the most active but still with
an IC50 ca. 27-fold higher than free CDDP; conjugates 44
and 45 were ca. 180-fold less active than free cisplatin
towards A2780 ovarian and MCF-7 breast cancer cell
lines. The reduced cytotoxicity was attributed to a low
receptor-mediated response [43].
Polymer carriers
Nowotnik et al. have reviewed the nano-polymer, Pro-
LindacTM (46), consisting of the active {Pt(R,R-dach)}2+
fragment of oxaliplatin bound to hydroxypropylmetha-
cryl-amide (HMPA). Release of the active platinum
pharamacophore was ca. seven-times greater at pH 5.4
in comparison to pH 7.4 after 24 hours. The superior
activity of ProLindacTM over oxaliplatin was shown in
both human and mouse xenograft models, while the
cytotoxicity profile of 46 was similar to oxaliplatin [2,44].
Release of nitric oxide (NO) from prodrugs is usually
activated by glutathione reductase in tumour cells result-
ing in growth inhibition of cancerous tissues. Duan et al.
have synthesised both hydrophilic poly(acrylic)-cis-
[Pt(NH3)2(carboxylate)2] (47 and 48) and hydrophobic
NO-donating (49) prodrugs (Figure 3h) combining NO
prodrug therapy with Pt based-therapy. The extended
life-times of both prodrugs suggest potential future use in
combination therapy. The Pt-prodrugs exhibited lower
cytotoxicity compared to free CDDP, attributable to the
slow release of the PtIV complex from the polymer con-
jugate [45].
Yang et al. have synthesised various PtIV coordinated
polymers which incorporate mPEG550 to increase poly-
mer solubility (Figure 3i). Conjugates 51 and 52 displayed
higher cytotoxicity towards MDA-MB-468 breast carci-
noma cells in comparison to the starting monomer [46].
Aryal et al. have synthesized an acid-responsive polymer-
conjugated to a PtIV prodrug, Bi(PEG-PLA)-
PtIV(Figure 3j) for the delivery of cisplatin to tumour
cells. Polymer conjugate 53 was cytotoxic towards A2780
human ovarian cancer cells. The release of CDDP from
the polymer conjugate is pH dependent, activated only in
acidic environments [47].
Vieira et al. sandwiched (aquated) cisplatin between two
oppositely charged polyelectrolytes, chitosan (CH) and
CMC to deliver cisplatin effectively to SK-mel-28 human
melanoma cells. The degree of acetylation of glucosa-
mine monomers in the CH was modified. In vitro CDDP-
CMC-CH75 (75% deacetylated) was 10-fold more active
towards SK-mel-28 cells than CDDP, whereas CDDP-
CMC-CH25 (25% deacetylated) was only 1.6-fold more
active. The 10-fold activity of the CDDP-CMC-CH75www.sciencedirect.com
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for the use of these polyelectrolytes as carriers [48].
Micelle carriers
Xiao et al. have synthesised a biodegradable di-block
amphiphilic copolymer (mPEG-b-P(LA-co-MCC) bear-
ing carboxylate groups for PtII chelation (54). The cyto-
toxicity of 54 towards EMT6 breast cancer cells was lower
than that of cisplatin, but comparable to oxaliplatin. The
reduced side effects associated with targeted delivery
suggest potential use of this polymer conjugate as a
targeted carrier vehicle [49].
Duong et al. have conjugated a PtIV-succinato prodrug to a
polymer backbone while simultaneously cross-linking the
core of the micellar structure (55). The release of cisplatin
from 55 was 80% within three weeks in the presence of
sodium ascorbate (5 mM) as a reductant at 37 8C. The
copolymer was inactive towards A549 lung cancer cells,
whereas both the PtIV prodrug and 55 displayed compar-
able activity. However, their cytotoxic activities are diffi-
cult to compare on account of their different mechanisms
of action [50].
Huynh et al. synthesised platinum amphiphilic block copo-
lymers (micelles, 56), by conjugating aquated CDDP to the
deprotected monomer 1,1-di-tert-buty; 3-2(2-methacryloy-
loxy)ethyl) butane-1,1,3-tricarboxylate (MAETC). Before
conjugation with CDDP, the polymers were non-toxic to
A549 lung cancer cells. The polymer bearing the shortest
block length displayed the highest activity, perhaps due to
fast release of CDDP [51]. Developing on this work,
Huynh et al. generated three different block copolymers
by varying the spacer lengths and chain extension. Con-
jugation with aqueous CDDP produced macromolecular
drugs related to carboplatin. Activity was tested against
three cancer cell lines, A549 lung, OVCAR3 and SKOV3
ovarian cancer cells with only the block copolymer with the
longest spacer length having an IC50 (10.3 mM) comparable
to free cisplatin (7.2 mM) [52].
Preclinical evaluation of the drug delivery micelles NC-
6004, composed of PEG, a hydrophilic chain, PGA and
carboxylate-bound {cis-Pt(NH3)2}
2+ fragments (57) has
confirmed a long blood retention time for the
platinum-conjugate in comparison to free cisplatin; the
maximum Pt accumulation for 57 occurred at 48 hours
compared to 10 min for cisplatin. The cytotoxicity of 57
was comparable to free cisplatin in mice implanted with
MKN-45 human gastric cancer cells [53].
Xue et al. have synthesised polymer–Pt complex nano-
micelles from folate-conjugated PEG-graft-a,b-poly[(N-
amino acidyl)-aspartamide] (FA-PEG-g-PAAsp) and
aqueous CDDP(58), also with conjugation to various
amino acids FA-PEG-g-PAsp-X (X = aminomalonate,
Ami; L-glutamate, Glu; L-aspartate, Asp). Cellular uptakewww.sciencedirect.com was higher for the folate-conjugated-Ami-CDDP towards
KB (FR +ve) epidermoid carcinoma cells in contrast to
the non-targeted Ami-CDDP micelles. All the FA-con-
jugated amino acid-CDDP micelles were less potent than
free CDDP, but their reduced toxicity makes them
potentially attractive drug carriers [54].
Liposomes possess a number of drawbacks limiting their
translation into the clinic, including drug release in plasma,
non-targeting, and non-uniform composition. In contrast,
dendrimers can have defined structures in which the core
consists of a functional monomer with a minimum of two
functional groups to allow additional layers, so called gener-
ations. Haririan et al. have synthesised two dendrimers (with
a PEG unit as the core and citric acid CA on the periphery)
G1 with MW 1000 Da and G2 with MW 2000 Da
conjugated to cisplatin forming G1 + CDDP and
G2 + CDDP. G2 + CDDP showed greater cytotoxicity
towards both sensitive and resistant HT1080 human fibro-
sarcoma cells, CT26 fibroblasts and SKOV3 human ovarian
cells compared to the parent cisplatin drug, while
G1 + CDDP demonstrated greater cytotoxicity towards
HT1080 and CT26 cell lines. Enhanced cytotoxicity of
both conjugates over CDDP is encouraging for the potential
use of platinum-dendrimer conjugates as drug carriers [55].
Radiation-activated prodrugs —
photoactivation
Another way of avoiding unnecessary damage to normal
tissues and delivering the active drug mainly to the tumour
itself is by the use of spatially directed radiation to enhance
activity or activate the drug specifically in the cancer cells.
One approach involves the use of high energy radiation
such as x-rays. Administration of a radiosensitiser can
potentially overcome the resistance of cancer cells towards
radiotherapy on account of their low O2 content (hypoxia).
Several platinum complexes including CDDP are known
to be radiosensitisers. It is possible to enhance the effects of
radiation by the use of less toxic platinum complexes. We
shall not discuss this mode of targeting further here,
although it is still of interest clinically.
Recent interest has focussed on the use of light for spatially
directed drug activation. Current clinical use of photody-
namic therapy involves administration of a photosensitiser
such as a porphyrin (‘Photofrin’) which absorbs red light
and converts ground state 3O2 into excited state
1O2 which
is highly damaging to cancer cells [56]. Hence, as with
radiosensitisation, this is less effective when cells are
hypoxic. One class of platinum complexes which do not
appear to rely on oxygen for activity are PtIV diazides.
Dihydroxidodiam(m)ine platinum(IV) diazido complexes
(e.g. 59 and 60, Figure 4f) are relatively inert in the dark
and importantly are not readily reduced by the thiol tri-
peptide glutathione, present in most cells at millimolar
concentrations. These PtIV complexes possess intenseCurrent Opinion in Chemical Biology 2013, 17:175–188
184 Bioinorganic Chemistry
Figure 4
(a) (b)
(c)
(e)
(h)
(f) (g)
(d)
(54)
(55)
(57)
PEG
OOC
OOC
OOC
OOC
PtPt
H3N
H3N
H3N
H3N
(56)
(59) (61)
(62)(58)
H3C
H3N
H2N NH2
NH3
H3N H3N
H3N
N3 N3
NN3 N3
OH
OH OH
OH
Pt
(60)
(63)
H3N
H3N
H3N
PtII-mono/bis Guanine adducts
H3N
N3
N3
N3
hνN3
N3 N
N
N
+  N3
+ DNA
N
N3 N3
NH3
OH
OH
OH
OH
OH
OH
OH
OH
HO
OH
Pt
Pt
Pt
CH3
H3C
H2C
m
n
SHC
C
C
H
Pt
Pt
O
n m
z
n
n
y x
z y x
O
O
O
O
O
OO
O
O
O
O
O
O
OO
HO
O
O
O
H S
S
O O
O
S
S
H H2C
H
C
C
H2C
H2
CH3 CH 3
CH3
CH3
CH3
C C
H2CC
H2
CH3 CH3 CH3
CH3
CH3
NH3
H3C
H3N
CH3H3C
CH3
C C
C
C
NH
NH
H
N
NH
NH
HN
H2C
O
O
O
O O
Cl
Cl
C
C
O
O
O
Pt
O
O
C
OO O
O
O
C
•
+  2N3 3N2
•
Current Opinion in Chemical Biology
PtIII–N
PtII
PtIV
H3N NH3
NH3
NH3
Pt
Pt
O
O
OOO
OO
O
O
OO
OO
O
O
F
Q
P
R = CH3 or FA
R
HNHN
HN HN
NH
N
H
n
Current Opinion in Chemical Biology 2013, 17:175–188 www.sciencedirect.com
Targeted delivery of platinum-based anticancer complexes Butler and Sadler 185ligan-(azide)-to-PtIV charge-transfer bands suitable for
photoactivation. The excited states (which are populated
in femto/pico-seconds) can have different geometries in-
cluding lengthened and weakened Pt–ligand bonds [57].
Interestingly, the trans diam(m)ine diazido complexes (60)
appear to be more effective as photoactivatable anticancer
agents than the cis isomers [58]. These complexes are also
more effective than cisplatin when used under conditions
appropriate for clinical phototherapeutic drugs (short treat-
ment times and short irradiation times).
Introduction of pyridine ligands instead of ammonia leads
to a marked increase in potency and activity at longer
wavelengths (61). For example, the trans di-pyridine
complex 62 is active with UVA, blue and green light
against a range of cancer cells at low micromolar doses
[59]. Longer wavelengths are of special interest because
they penetrate more deeply into tissue than short wave-
lengths. Activating platinum complexes which do not
possess long wavelength absorption bands is possible
using two photons of red light as fast laser pulses [60].
The activity of the complex trans,trans,trans-
[Pt(N3)2(OH)2(NH3)(pyridine)] (62) towards oesopha-
geal cancer is enhanced in vivo when irradiated with blue
light [61]. The mechanism of action appears distinct
from that of conventional platinum drugs such as cispla-
tin. One route of photodecomposition involves two one-
electron transfers from the azido ligands generating N2
and PtII (Figure 4h) which can then form DNA lesions.
These lesions can be interstrand (e.g. trans bis-guanine)
and different from those formed by cisplatin.
Recent work suggests that there may be a role for the
released azidyl radicals in the mechanism of action.
Such radicals can be readily trapped and characterised
by EPR and quenched by the amino acid tryptophan
which can protect cancer cells in vitro [62]. Further-
more, Pracharova et al. assessed the importance of DNA
binding for the cytotoxicity induced by photoactivated
62. Major DNA adducts of photoactivated 62 are able to
stall RNA polymerase II more efficiently than cisplatin,
suggesting that transcription inhibition may contribute
to the cytotoxicity of photoactivated PtIV complexes
[63].
Carboplatin irradiated with UVA (365 nm) is more potent
(>10-fold) than non-photoactivated carboplatin in A2780
ovarian cancer cells. Short UVA-irradiation of carboplatin
(30 min) resulted in 74% mono-functional DNA adducts
while prolonged irradiation for four hours converted all
mono adducts to bi-functional adducts [64].(a) PtII micelle conjugate (54). (b) Platinum(IV) cross-linked within a highly fu
Amphiphilic platinum(II) block copolymers (56). (d) NC-6004 Pt polymeric m
Dihydroxidodiam(m)ine platinum(IV) diazido complexes, cis (59) and trans (6
diazido complexes. (h) Schematic photodecomposition pathway for dihydro
www.sciencedirect.com Conclusions
Platinum drugs cisplatin, carboplatin and oxaliplatin are
currently successful for treating some types of cancer, but
have problems associated with toxic side-effects, the de-
velopment of resistance and lack of tumour selectivity.
Promising current work shows that these problems can be
overcome to some extent by improved delivery and target-
ing. For example, platinum complexes can be encapsu-
lated in nanotubes, liposomes, biodegradable proteins and
other polymers and attached to the surfaces of nanotubes,
nanorods and other nanoparticles. Encapsulation can be
accompanied by wrapping and capping. One advantage of
using carriers is that they can be multifunctional, contain-
ing not only the Pt drug or prodrug but also targeting
molecules such as cell-penetrating peptides, aptamers,
antibodies and various overexpressed receptors. Some
nanoparticles can also be made magnetic or can be acti-
vated thermally. Encapsulation can also protect reactive
platinum complexes from activation before they reach the
target site. Initial data indicate that such polymer and
nanoparticle supports can be well-tolerated by cells. The
preparation (homogeneity) and characterisation of such
multi-functionalised platinated systems, which unlike
small Pt complexes cannot be crystallised, presents a
challenge for translation into the clinical use. Targeting
by spatially directed activation of photoactivatable PtIV
prodrugs using light is also a promising way of avoiding
damage to non-tumour tissue. Moreover, it is evident that
these new designs of transport and delivery systems for Pt
prodrugs can lead to the release of novel species which can
kill cancer cells by new mechanisms, itself a potentially
useful way of combating resistance and extending the
spectrum of anticancer activity.
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